Respiratory · Clinical trials
Sarcoidosis Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About sarcoidosis — and why its trials are hard
Sarcoidosis is a multisystem granulomatous disease of unknown cause characterised by non-caseating granulomas most often affecting the lungs and intrathoracic lymph nodes, but also skin, eyes, heart, liver and nervous system. Presentation ranges from asymptomatic hilar adenopathy to progressive pulmonary fibrosis and life-threatening cardiac or neurologic involvement. Many cases remit spontaneously, complicating trial design. Corticosteroids (prednisone) are the mainstay first-line therapy despite scarce placebo-controlled evidence, with methotrexate, azathioprine and other immunosuppressants used as steroid-sparing agents and anti-TNF antibodies (notably infliximab) reserved for refractory disease. Approved pharmacotherapy specific to sarcoidosis is limited: repository corticotropin injection (Acthar Gel) carries a long-standing FDA indication for symptomatic sarcoidosis. The field is marked by repeated trial disappointments, including ustekinumab and golimumab, which failed to meet their primary endpoints in chronic pulmonary and skin sarcoidosis. Heterogeneity, high spontaneous remission and imperfect endpoints continue to challenge drug development, and no modern targeted biologic has achieved a broad sarcoidosis approval.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Repository corticotropin injection (Acthar Gel) | (unverified) long-standing FDA indication for symptomatic sarcoidosis | Symptomatic sarcoidosis (adjunctive/steroid-context use) | (unverified) approval predates modern randomised pivotal-trial requirements | (unverified) | (unverified) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in sarcoidosis development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Ustekinumab and golimumab — Phase 2 randomised trial in chronic pulmonary and/or skin (lupus pernio) sarcoidosis (Judson et al., Eur Respir J 2014) | Neither agent met the primary endpoint of improvement in lung function (FVC) or skin disease versus placebo | Disease heterogeneity, insensitive endpoints, high placebo/spontaneous improvement rates and possibly inadequate treatment duration |
| Adalimumab / other anti-TNF and immunomodulators — Small trials in refractory sarcoidosis | Inconsistent or modest benefit; failed to establish robust disease-modifying efficacy in adequately powered pivotal trials | Small sample sizes, variable organ involvement and lack of validated, sensitive primary endpoints |
Choosing the right endpoint
Primary endpoints that matter in sarcoidosis trials
- Forced vital capacity (FVC) — Primary lung-function endpoint in pulmonary sarcoidosis trials; often insensitive given slow disease change
- Corticosteroid dose reduction — Steroid-sparing effect is a clinically important efficacy measure
- Chest imaging / Scadding stage — Radiographic assessment of parenchymal and nodal involvement
- Skin (lupus pernio) severity scores — Used in cutaneous sarcoidosis endpoints
- Patient-reported outcomes / fatigue — Fatigue and quality of life are common but hard-to-quantify secondary endpoints
How iNGENū runs sarcoidosis trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Sarcoidosis clinical trials — FAQs
What is first-line treatment for sarcoidosis?
Are there drugs approved specifically for sarcoidosis?
Why have many sarcoidosis trials failed?
Ready to discuss your sarcoidosis trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal